Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit ...

Amid pressure from the White House, U.S. drug companies are experimenting with direct-to-consumer sales models that cut out the middlemen.

More than one in four U.S. adults with diabetes used one of the injectable medicines that target the GLP-1 protein last year, the U.S. Centers for Disease Control and Prevention said on Thursday. The ...

Eli Lilly's new oral GLP-1 medication orforglipron produced an average weight loss of 12.4% (27.3 pounds) in clinical trials.

With a market cap of $3.1 billion, Scholar Rock Holding Corporation appears fairly valued for now. Click here to read an ...

Texas has sued pharmaceutical giant Eli Lilly for allegedly bribing and illegally inducing medical providers to prescribe its ...

The Q2 pharma earnings season featured changes in the obesity race as well as insights into drugmakers’ views on tariffs and drug pricing.

Doctors advise most patients on GLP-1 obesity drugs such as Wegovy and Zepbound to stay on them to keep the weight off, but ...

In this week’s InnovationRx newsletter, we look at longevity drugs for dogs, programmable mRNA for fighting cancer, AI models ...

What Happened: Skovronsky demonstrated confidence in Eli Lilly by purchasing 1,000 shares, as reported in a Form 4 filing with the U.S. Securities and Exchange Commission on Tuesday. The total value ...

Novo Nordisk NVO faced a significant setback in July after sharply reducing its 2025 outlook for both sales and operating ...

Texas Attorney General Ken Paxton claims that through an alleged kickback scheme Eli Lilly “fraudulently sought to maximize profits at taxpayer expense.” ...